Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age
Top Cited Papers
- 14 January 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 141 (2), 100-111
- https://doi.org/10.1161/circulationaha.119.044133
Abstract
Background: The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) showed that dapagliflozin added to other guideline-recommended therapies reduced the risk of mortality and heart failure hospitalization and improved symptoms in patients with heart failure and reduced ejection fraction. We examined the effects of dapagliflozin according to age, given potential concerns about the efficacy and safety of therapies in the elderly. Methods: Patients in New York Heart Association functional class II or greater with a left ventricular ejection fraction <= 40% and a modest elevation of NT-proBNP (N-terminal pro-B-type natriuretic peptide) were eligible. Key exclusion criteria included systolic blood pressure <95 mm Hg and estimated glomerular filtration rate <30 mL center dot min(-1)center dot 1.73 m(-2). The primary outcome was the composite of an episode of worsening heart failure (heart failure hospitalization or urgent heart failure visit) or cardiovascular death, whichever occurred first. Results: A total of 4744 patients 22 to 94 years of age (mean age, 66.3 [SD 10.9] years) were randomized: 636 patients (13.4%) were = 75 years of age. The rate of the primary outcome (per 100 person-years, placebo arm) in each age group was 13.6 (95% CI, 10.4-17.9), 15.7 (95% CI, 13.2-18.7), 15.1 (95% CI, 13.1-17.5), and 18.0 (95% CI, 15.2-21.4) with corresponding dapagliflozin/placebo hazard ratios of 0.87 (95% CI, 0.60-1.28), 0.71 (95% CI, 0.55-0.93), 0.76 (95% CI, 0.61-0.95), and 0.68 (95% CI, 0.53-0.88; P for interaction=0.76). Consistent benefits were observed for the components of the primary outcome, all-cause mortality, and symptoms. Although adverse events and study drug discontinuation increased with age, neither was significantly more common with dapagliflozin in any age group. Conclusions: Dapagliflozin reduced the risk of death and worsening heart failure and improved symptoms across the broad spectrum of age studied in DAPA-HF. There was no significant imbalance in tolerability or safety events between dapagliflozin and placebo, even in elderly individuals.This publication has 23 references indexed in Scilit:
- Mismatch between heart failure patients in clinical trials and the real worldInternational Journal of Cardiology, 2013
- Patient Characteristics From a Regional Multicenter Database of Acute Decompensated Heart Failure in Asia Pacific (ADHERE International–Asia Pacific)Journal of Cardiac Failure, 2012
- Adverse Drug Events and Associated Factors in Heart Failure Therapy Among the Very ElderlyCanadian Geriatrics Journal, 2011
- Pharmacotherapy of heart failure in the elderly: adverse eventsHeart Failure Reviews, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsThe New England Journal of Medicine, 2011
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programmeEuropean Heart Journal, 2008
- A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomialsStatistics in Medicine, 2004
- Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialThe Lancet, 2003
- Semiparametric Regression for the Mean and Rate Functions of Recurrent EventsJournal of the Royal Statistical Society Series B: Statistical Methodology, 2000